Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines

Abstract

The NF-κB transcription factor has been shown to inhibit apoptosis in several experimental systems. We therefore investigated whether the expression of the Bax proapoptotic protein could be influenced by NF-κB activity. Increased Bax protein expression was detected in HCT116, OVCAR-3 and MCF7 cells stably expressing a mutated unresponsive IκB-α inhibitory protein that blocks NF-κB activity. Northern blots showed that bax mRNA expression was increased as a consequence of mutated IκB-α expression in HCT116 cells. A careful examination of the human bax gene promoter sequence showed three putative binding sites for NF-κB, and the κB2 site at position -687 could indeed bind NF-κB complexes in vitro. Transient transfection of a bax promoter luciferase construct in HCT116 cells showed that NF-κB proteins could partially inhibit the transactivation of the bax promoter by p53. Mutations or deletions of the κB sites, including κB2, indicated that this NF-κB-dependent inhibitory effect did not require NF-κB DNA-binding, and was thus an indirect effect. However, cotransfection of expression vectors for several known cofactors failed to identify a competition between p53 and NF-κB for a transcription coactivator. Our findings thus demonstrate for the first time that NF-κB regulates, through an indirect pathway, the bax gene expression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

Abbreviations

NF-κB:

Nuclear Factor-κB

IκB:

inhibitor of κB

TNF:

tumor necrosis factor

EMSA:

electrophoretic mobility shift assay

References

  • Adams JM, Cory S . 1998 Science 281: 1322–1326

  • Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K . 1997 Cell 89: 1175–1184

  • Baldwin AS . 1996 Annu. Rev. Immunol. 14: 649–681

  • Bargou RC, Emmerich F, Krappmann D, Bomert K, Mapara MY, Arnold W, Royer HD, Grinstein E, Greiner A, Scheidereit C, Dörken B . 1997 J. Clin. Invest. 100: 2961–2969

  • Beg AA, Baltimore D . 1996 Science 274: 782–784

  • Bentires-Alj M, Hellin AC, Ameyar M, Chouaib S, Merville MP, Bours V . 1999 Cancer Res. 59: 811–815

  • Bonizzi G, Dejardin E, Piret B, Piette J, Merville M-P, Bours V . 1996 Eur. J. Biochem. 242: 544–549

  • Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck R-P, Bravo R, Kelly K, Siebenlist U . 1992 Mol. Cell. Biol. 12: 685–695

  • Brach MA, Hass R, Sherman ML, Gunji H, Weichselbaum R, Kufe D . 1991 J. Clin. Invest. 88: 691–695

  • Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U . 1995 Science 267: 1485–1488

  • Cai Z, Körner M, Tarantino N, Chouaib S . 1997 J. Biol. Chem. 272: 96–101

  • Chao DT, Korsmeyer SJ . 1998 Annu. Rev. Immunol. 16: 395–419

  • Chariot A, Princen F, Gielen J, Merville MP, Franzoso G, Brown K, Siebenlist U, Bours V . 1999 J. Biol. Chem. 274: 5318–5325

  • Chen F, Demers LM, Vallyathan V, Lu Y, Castranova V, Shi X . 1999 J. Biol. Chem. 274: 35591–35595

  • Das KC, White CW . 1997 J. Biol. Chem. 272: 14914–14920

  • Dejardin E, Bonizzi G, Bellahcène A, Castronovo V, Merville M-P, Bours V . 1995 Oncogene 11: 1835–1841

  • Dejardin E, Deregowski V, Chapeliker M, Gielen J, Merville M-P, Bours V . 1999 Oncogene 18: 2567–2577

  • Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C . 1996 Mol. Cell. Biol. 16: 4295–4304

  • Ferreira V, Tarantino N, Körner M . 1998 J. Biol. Chem. 273: 592–599

  • Friess H, Lu Z, Graber HU, Zimmermann A, Adler G, Korc M, Schmid RM, Buchler MW . 1998 Gut 43: 414–421

  • Gerritsen ME, Williams AJ, Neish AS, Moore S, Shi Y, Collins T . 1997 Proc. Natl. Acad. Sci. USA 94: 2927–2932

  • Gu W, Shi XL, Roeder RG . 1997 Nature 387: 819–823

  • Hellin A-C, Calmant P, Gielen J, Bours V, Merville M-P . 1997 Oncogene 16: 1187–1195

  • Jayaraman L, Moorthy NC, Murphy KG, Manley JL, Bustin M, Prives C . 1998 Genes Dev. 12: 462–472

  • Jones PL, Ping D, Boss JM . 1997 Mol. Cell. Biol. 17: 6970–6981

  • Krikos A, Laherty CD, Dixit VM . 1992 J. Biol. Chem. 267: 17971–17976

  • Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G . 1999 Proc. Natl. Acad. Sci. USA 96: 9136–9141

  • Miyashita T, Harigai M, Hanada M, Reed JC . 1994a Cancer Res. 54: 3131–3135

  • Miyashita T, Krajewski S, Krajewska M, Wang HG, Link HK, Liebermann DA, Hoffman B, Reed JC . 1994b Oncogene 9: 1799–1805

  • Miyashita T, Reed JC . 1995 Cell 80: 293–299

  • Na S-Y, Lee S-K, Han S-J, Choi H-S, Im S-Y, Lee JW . 1998 J. Biol. Chem. 273: 10831–10834

  • Oren M . 1999 J. Biol. Chem. 274: 36031–36034

  • Perera P-Y, Qureshi N, Vogel SN . 1996 Infect. Immun. 64: 878–884

  • Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, Nabel GJ . 1997 Science 275: 523–527

  • Piret B, Piette J . 1996 Nucl. Acids Res. 24: 4242–4248

  • Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady JN . 2000 Mol. Cell. Biol. 20: 3377–3386

  • Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M . 1997 Science 275: 967–969

  • Ravi R, Mookerjee B, van Hensbergen Y, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ, Bedi A . 1998 Cancer Res. 58: 4531–4536

  • Reed JC . 1998 Oncogene 17: 3225–3236

  • Reed JC . 1999 J. Clin. Oncol. 17: 2941–2953

  • Schmidt T, Korner K, Karsunky H, Korsmeyer S, Muller R, Moroy T . 1999 Cell Death Differ. 6: 873–882

  • Schmitz ML, Stelzer G, Altmann H, Meisterernst M, Baeuerle PA . 1995 J. Biol. Chem. 270: 7219–7226

  • Scolnick DM, Chehab NH, Stavridi ES, Lien MC, Caruso L, Moran E, Berger SL, Halazonetis TD . 1997 Cancer Res. 57: 3693–3696

  • Sheppard KA, Rose DW, Haque ZK, Kurokawa R, McInerney E, Westin S, Thanos D, Rosenfeld MG, Glass CK, Collins T . 1999 Mol. Cell Biol. 19: 6367–6378

  • Siebenlist U, Franzoso G, Brown K . 1994 Annu. Rev. Cell. Biol. 10: 405–455

  • Sovak MA, Bellas RE, Kim DW, Zanievski GJ, Rogers AE, Traish AM . 1997 J. Clin. Invest. 100: 2952–2960

  • Steegenga WT, Shvarts A, Riteco N, Bos JL, Jochemsen AG . 1999 Mol. Cell. Biol. 19: 3885–3894

  • Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J . 1998 J. Exp. Med. 188: 211–216

  • Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA . 1998 J. Clin. Oncol. 16: 2583–2590

  • Tamatani M, Che YH, Matsuzaki H, Ogawa S, Okado H, Miyake S, Mizuno T, Tohyama M . 1999 J. Biol. Chem. 274: 8531–8538

  • Thanos D, Maniatis T . 1992 Cell 71: 777–789

  • Tsujimoto Y, Cossman J, Jaffe E, Croce CM . 1985 Science 228: 1440–1443

  • Tsukahara T, Kannagi M, Ohashi T, Kato H, Arai M, Nunez G, Iwanaga Y, Yamamoto N, Ohtani K, Nakamura M, Fujii M . 1999 J. Virol. 73: 7981–7987

  • Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM . 1996 Science 274: 787–789

  • Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES, Collins T . 1999 J. Biol. Chem. 274: 1879–1882

  • Wang C-Y, Mayo MW, Baldwin AS . 1996 Science 274: 784–787

  • Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS . 1999 Nat. Medicine 5: 412–417

  • Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS . 1998 Science 281: 1680–1683

  • Webster GA, Perkins ND . 1999 Mol. Cell Biol. 19: 3485–3495

  • Whiteside ST, Ernst MK, LeBail O, Laurent-Winter C, Rice N, Israël A . 1995 Mol. Cell. Biol. 15: 5339–5345

  • Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, Fitzgerald MJ, Rothstein TL, Sherr DH, Sonenshein GE . 1996 EMBO J. 15: 4682–4690

  • Zhan Q, Fan S, Bae I, Guillouf C, Liebermann DA, O'Connor PM, Fornace Jr AJ . 1994 Oncogene 9: 3743–3751

  • Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BL, El-Deiry WS . 1998 Oncogene 16: 1713–1721

  • Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C . 1999 Genes Dev. 13: 382–387

Download references

Acknowledgements

M-P Merville and C Van Lint are Research Associates and V Bours is a Senior Research Associate at the National Fund for Scientific Research (FNRS, Belgium). P Viatour is supported by a Télévie fellowship (FNRS, Belgium). This research was supported by grants from the ‘Centre Anti-Cancéreux’ (Liège, Belgium), the FRSM (Belgium) and from the ‘Concerted Action Program convention 97/02-214’, Communauté Française de Belgique.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bentires-Alj, M., Dejardin, E., Viatour, P. et al. Inhibition of the NF-κB transcription factor increases Bax expression in cancer cell lines. Oncogene 20, 2805–2813 (2001). https://doi.org/10.1038/sj.onc.1204343

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204343

Keywords

This article is cited by

Search

Quick links